Syngeneic bone marrow expressing a single donor class I MHC molecule permits acceptance of a fully allogeneic cardiac allograft

Transplantation
W WongK J Wood

Abstract

Bone marrow cells may be a useful vehicle for pretransplant delivery of alloantigen to induce tolerance in vivo. However, infusion of fully allogeneic bone marrow cells carries the risk of graft-versus-host disease. In order to reduce this risk while retaining the tolerogenic potential of the bone marrow infusion, we have investigated the ability of recipient bone marrow cells expressing a single donor MHC class I antigen to induce specific unresponsiveness in vivo. We show that 5x10(7) and 5x10(6) bone marrow cells from a transgenic strain of CBA mice, CBK, that express a single donor class I MHC gene, H2Kb (H2k + H2Kb), were able to induce long term survival of a fully allogeneic C57BL/10 (H2b) cardiac allograft in 80% and 20% of unmanipulated CBA (H2k) recipients, respectively, when administered intravenousely on the day of transplantation. In contrast, the same doses of fully allogeneic C57BL/10 donor bone marrow were completely ineffective at prolonging graft survival. When the interval between bone marrow infusion and transplantation was increased to 14 days, CBK bone marrow at either dose (5x10(6) and 5x10(7)) induced long term survival of C57BL/10 cardiac allografts in all recipients (MST>100 days) while fully allogenei...Continue Reading

References

Jun 27, 1992·Lancet·T E StarzlM Trucco
Aug 21, 1992·Science·F Ramsdell, B J Fowlkes
Jun 1, 1991·Annals of Internal Medicine·M H SayeghN L Tilney
Aug 1, 1987·European Journal of Immunology·S QinH Waldmann
Mar 1, 1989·The Journal of Experimental Medicine·S X QinH Waldmann
Jan 1, 1987·Annual Review of Immunology·R A Clift, R Storb
Aug 1, 1986·Transplantation·R A SuperinaP J Morris
Jun 10, 1994·Science·G LombardiR Lechler

❮ Previous
Next ❯

Citations

Aug 11, 2001·Transplantation Proceedings·R EmirogluM Haberal
Dec 26, 2001·Transplantation Proceedings·G J PettigrewJ A Bradley
Feb 20, 2003·Transplantation Proceedings·M ShrotriJ A Bradley
Jun 18, 1999·Transplantation Proceedings·K J Wood
Dec 6, 2003·Transplantation·Peter J Morris, Anthony P Monaco
Jan 6, 2015·Molecular Therapy. Methods & Clinical Development·Brandon K SackDavid M Markusic
Jun 18, 2010·Kidney International·Thomas T TapmeierWilson Wong
May 26, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·K J WoodP J Morris
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masaaki KataokaM Wayne Flye
Sep 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam D GriesemerKazuhiko Yamada
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kevin J YoungLi Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.